An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma

FASEB Journal

Volumn 14, Issue 2, 2000, Pages 301-311

  Yoon, Sam S ^a   Nakamura, Hideo ^a   Carroll, Nancy M ^a   Bode, Barrie P ^a   Chiocca, E Antonio ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Gene therapy; HSV1; Ribonucleotide reductase

Indexed keywords

BETA GALACTOSIDASE; ONCOLYTIC VIRUS; RIBONUCLEOTIDE REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER THERAPY; COLON CARCINOMA; CYTOTOXICITY; DNA MODIFICATION; GENE THERAPY; HERPES SIMPLEX VIRUS 1; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1;

EID: 0033950232     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fasebj.14.2.301     Document Type: Article

References (44)

1. Dranoff, G. (1998) Cancer gene therapy: connecting basic research with clinical inquiry. J. Clin. Oncol. 16, 2548-2556
2. Jolly, D. (1995) Viral vector systems for gene therapy. In The Internet Book of Gene Therapy (Sobol, R. E., and Scanlon, K. J., eds) pp 3-16, Appleton and Lange: Stamford
3. Roth, J. A., and Cristiano, R. J. (1997) Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89, 21-39
4. Kirn, D., Mermiston, T., and McCormick, F. (1998) Onyx-015: Clinical data are encouraging [letter to the editor]. Nature Med. 4, 1341-1342
5. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376
6. Hall, A. R., Dix, B. R., O'Carroll, S. J., and Braithwaite, A. W. (1998) p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med. 4, 1068-1072
7. Goodrum, F. D., and Ornelles, D. A. (1998) p53 status does not determine outcome of EIB 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72, 9479-9490
8. Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., and zur Hausen, H. (1998) Replication of Onyx-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72, 9470-9478
9. Coffey, M. C., Strong, J. E., Forsyth, P. A., and Lee, P. W. K. (1998) Reovirus therapy of tumors with activated ras pathway. Science 282, 1332-1334
10. Strong, J. E., Coffey, M. C., Tang, D., Sabinin, P., and Lee, P. W. K. (1998) The molecular basis of viral oncolysis: usurpation of the ras signaling pathway by reovirus. EMBO J. 17, 3351-3362
11. Johnson, P. A., Miyanohara, A., Levine, F., Cahill, T., and Friedmann, T. (1992) Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J. Virol.66, 2952-2965
12. Johnson, P. A., Yoshida, K., Gage, F. H., and Friedmann, T. (1992) Effects of gene transfer into cultured CNS neurons with a replication-defective herpes simplex virus type 1 vector. Mol. Brain Res. 12, 95-102
13. Roizman, B., and Sears, A. E. (1996) Herpes simplex viruses and their replication. In Fields Virology (Fields, B. N., Knipe, D. M., Howley, P. M., et al., eds) Third Ed, pp. 2231-2295, Lippincott-Raven Publishers: Philadelphia
14. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856
15. Goldstein, D. J., and Weller, S. K. (1988) Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196-205
16. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938-943
17. Boviatsis, E. J., Park, J. S., Sena-Esteves, M., Kramm, C. M., Chase, M., Efird, J. T., Wei, M. X., Breakefield, X. O., and Chiocca, E. A. (1994) Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus that retains an intact thymidine kinase gene. Cancer Res. 54, 5745-5751
18. Li, A. P., Roque, M. A., Beck, D. J., and Kaminski, D. L. (1992) Isolation and culturing of hepatocytes from human livers. J. Tissue Culture Methods 14, 139-142
19. Yoon, S. S., Carroll, N. M., Chiocca, E. A., and Tanabe, K. K. (1998) Cancer gene therapy using replication-competent herpes simplex virus type 1. Ann. Surg. 228, 366-374
20. Deluca, N. A., McCarthy, A. M., and Schaffer, P. A. (1985) Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J. Virol. 56, 558-570
21. Rice, S. A., Lam, V., and Knipe, D. M. (1993) The acidic amino-terminal region of herpes simplex virus type 1 alpha protein ICP27 is required for an essential lytic function. J. Virol. 67, 1778-1787
22. Lelie, P. N., Reesink, H. W., and Lucas, C. J. (1987) Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine. J. Med. Virol. 23, 297-301
23. Carroll, N. M., Chiocca, E. A., Takahashi, K., and Tanabe, K. K. (1996) Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg. 224, 323-330
24. Higgins, G. M., and Anderson, R. M. (1931) Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal. Arch. Pathol. 12, 186-202
25. Morrison, L. A., and Knipe, D. M. (1994) Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J. Virol. 68, 689-696
26. Steer, C. J. (1995) Liver regeneration. FASEB J. 9, 1396-1400
27. Read, G. S., and Frenkel, N. (1983) Herpes simplex virus mutants defective in the virion-associated shutoff of host polypeptide synthesis and exhibiting abnormal synthesis of alpha (immediate early) viral polypeptides. J. Virol. 46, 498-512
28. Giavazzi, R., Jessup, J. M., Campbell, D. E., Walker, S. M., and Fidler, I. J. (1986) Experimental nude mouse model of human colorectal cancer liver metastases. J. Natl. Cancer Inst. 77, 1303-1308
29. Becker, T. M., Lee, F., Daling, J. R., and Nahmias, A. J. (1996) Seroprevalence of and risk factors for antibodies to herpes simplex viruses, hepatitis B, and hepatitis C among southwestern Hispanic and non-Hispanic white women. Sex. Transm. Dis. 23, 138-144
30. Herrlinger, U., Kramm, C. M., Aboody-Guterman, K. S., Silver, J. S., Ikeda, K., Johnston, K. M., Pechan, P. A., Barth, R. F., Finkelstein, D., Chiocca, E. A., Louis, D. N., and Breakefield, X. O. (1998) Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. 5, 809-819
31. Breakefield, X. O., Kramm, C. M., Chiocca, E. A., and Pechan, P. A. (1995) Herpes simplex virus vectors for tumor therapy. In The Internet Book of Gene Therapy (Sobol, R. E., and Scanlon, K. J., eds) pp. 41-56, Appleton and Lange, Stamford, Connecticut
32. Boviatsis, E. J., Scharf, J. M., Chase, M., Harrington, K., Kowall, N. W., Breakefield, X. O., and Chiocca, E. A. (1994) Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1, 323-331
33. Mineta, T., Rabkin, S. D., and Martuza, R. L. (1994) Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963-3966
34. Balzarini, J., Bohman, C., and De Clercq, E. (1993) Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl) guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J. Biol. Chem. 268, 6332-6337
35. Breakefield, X. O., and DeLuca, N. A. (1991) Herpes simplex virus for gene delivery to neurons. New Biol. 3, 203-218
36. Pagano, J. S., and Lemon, S. M. (1981) The herpesviruses. In Medical Microbiology and Infectious Diseases (Braude, A. I., ed) pp. 541-549, W. B. Saunders Co., Philadelphia
37. Toda, M., Martuza, R. L., Kojima, H., and Rabkin, S. D. (1998) In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464
38. Toda, M., Rabkin, S. D., Kojima, H., and Martuza, R. L. (1999) Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10, 385-393
39. Weiss, L., Grundmann, E., Torhorst, J., Hartveit, F., Moberg, I., Eder, M., Fenoglio-Preiser, C. M., Napier, J., Horne, C. H., Lopez, M. J., et al. (1986) Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol. 150, 195-203
40. Niederhuber, J. E., and Ensminger, W. D. (1993) Treatment of metastatic cancer to the liver. In Cancer. Principles and Practice of Oncology. (DeVita, V. T. J., Hellman, S., and Rosenberg, S. A., eds) pp. 2201-2225 J. B. Lippincott Co., Philadelphia
41. Enzminger, W. D., and Gyves, J. W. (1983) Clinical pharmacology of hepatic arterial chemotherapy. Semin. Oncol. 10, 176-182
42. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552
43. Carroll, N. M., Chiocca, E. A., and Tanabe, K. K. (1997) The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J. Surg. Res. 69, 413-417
44. Chase, M., Chung, R., and Chiocca, E. A. (1998) An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnol. 16, 444-448.